补气类中草药对缺氧性肝细胞生长作用的影响

目的观察补气类中草药对缺氧性肝细胞生长作用的影响,为进一步研究其促细胞生长机制奠定基础。方法用四甲基偶氮唑蓝(MTT)法、活细胞观察法分析细胞生长情况,并进行统计学处理。结果4种补气药(人参、党参、黄芪、西洋参)对正常肝细胞均有明显促生长作用(P<0.05),尤以人参效果最好。而对于缺氧性肝细胞则西洋参促生长效果最好(P<0.05);人参、党参效果虽优于黄芪,但差异无统计学意义(P>0.05)。结论不同补气药对正常肝细胞与缺氧性肝细胞的促生长作用不同:人参对正常肝细胞效果最好,西洋参对缺氧性肝细胞效果最好。     

抗真菌中药的作用机理研究进展

综述了 90年代以来在研究抗真菌中药作用机理方面取得的进展、存在的问题并对中药的抗真菌研究前景进行了展望。     

Holistic Approach to Functional Constipation: Perspective of Traditional Persian Medicine

Traditional Persian medicine (TPM) proposes a different viewpoint to the chronic diseases. Diagnosis and implemented treatment are based on individual differences among patients. Constipation or Ea''teghal-e-batn is a condition in which the patient develops difficult or painful defecation. Based on TPM concepts, the first digestion step starts from halq (oral cavity), and ends via defecation from the maq''ad (anus). Avicenna believed that four faculties, ha''zemeh (digestive), ja''zebeh (absorptive), ma''sekeh (retentive) and da''fe''eh (propulsive), are involved in the process of digestion and absorption of the ingested food and expelling the waste materials. The bowel movement and appearance of the stool is a measure for evaluating the gastrointestinal healthy function. Defecation should be with no pain and fecal material should have no burning and acuity. Low food intake or foods with dry temperament, dryness of gastrointestinal tract, diaphoresis and heavy exercise as well as intestine sensory loss were discussed as main causes of constipation. Management of constipation in TPM includes dietary schemes, oil massages and subsequently simple herbal medicines. According to TPM theories, the first step in treating a disease is the elimination of disease causes (asbab e-maraz) and also providing the causes of health (asbab-e-sehhat). Health care providers should know the proper condition which the herbal medicines should be administered in and be able to guide the patients about the benefits and hazards of herbal remedies, commonly used in their living origin.     

经典名方中玄参的本草考证

通过查阅历代本草、医籍、方书及近现代文献资料，对经典名方中所用饴糖的名称、品种、原料及制作工艺进行了考证，为含有饴糖的经典名方开发利用提供依据。经考证可知，饴糖之名历代多源于其形态、质地、制法、原料及产地。古代所用饴糖根据质地不同，主要分为软、硬两类，湿软如蜜者称为“饴”或“胶饴”，质硬色白的则称为“饧”“糖”，现代则多称为麦芽糖，入药仅用胶饴，饧则多作食用；历代药用胶饴推崇糯米（来源于Oryza sativa var. glutinosa）为原料，以大麦Hordeum vulgare制蘖，经过发酵、煎煮、浓缩制备而成，而粟米（来源于Setaria italica var. germanica）、黍Panicum miliaceum等其他谷物为原料制成的饴糖品质次之。2020年版《中华人民共和国药典》未收录饴糖，收载了药用辅料麦芽糖，为纯度较高的结晶粉；但国家食品标准与地方炮制规范中收录了饴糖。基于考证结果，建议经典名方开发中所用胶饴可参考GB/T 20883—2017中的麦芽糖浆，并明确以糯米、大麦为原料。     

The anti-arthritic activity of total glycosides from Pterocephalus hookeri,a traditional Tibetan herbal medicine

Context: Pterocephalus hookeri (C. B. Clarke) Hock., a traditional Tibetan herbal medicine rich in glycosides, has been used to treat several diseases including rheumatoid arthritis.

Objective: To evaluate the anti-arthritic activity of total glycosides from P. hookeri, and its possible mechanisms of action.

Materials and methods: Anti-arthritic activity of total glycosides from P. hookeri (oral administration for 30 days at 14–56?mg/kg) was evaluated using paw swelling, arthritis scores and histopathological measurement in adjuvant-induced arthritis (AA) Sprague-Dawley rats. The NF-κB p65 expression in synovial tissues, and serum superoxide dismutase (SOD) activity, malondialdehyde (MDA) and nitric oxide (NO) levels was measured in AA rats, respectively. Further assessment of anti-inflammatory and analgesic activities of these glycosides were carried out using inflammation and hyperalgesia models induced by xylene, carrageenan, agar and acetic acid, respectively.

Results: Total glycosides (56?mg/kg) decreased the paw swelling (38.0%, p?p?p?p?p?p?p?Discussion and conclusion: Our findings confirmed the anti-arthritic property of the total glycosides from P. hookeri, which may be attributed to its inhibition on NF-κB signalling and oxidative stress.     

医院制剂复方甘草口服溶液质量回顾分析

目的 对医院制剂复方甘草口服溶液进行质量回顾分析,及时发现并纠正生产过程的不良趋势,保证制剂质量.方法 采用单值-移动极差控制图法和风险级别判断矩阵对中国人民解放军联勤保障部队第九〇〇医院近五年生产的复方甘草口服溶液质量进行分析.结果 2014年6月至2019年6月,该院生产的30批次复方甘草口服溶液质量符合法定标准,控制图显示该品种生产工艺较稳定,针对复方甘草口服溶液中愈创木酚甘油醚含量波动较大的问题进行风险分析并采取了有效措施控制风险.结论 控制图分析结合风险管理,更有利于我院持续、稳定地生产出质量优异的复方甘草口服溶液.     

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

Lessons Learned

• A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies.
• This traditional Chinese medicine formulation can work with Western cancer chemotherapeutic agents to improve clinical outcomes or alleviate side effects for patients with advanced HCC.

BackgroundThis study aimed to evaluate efficacy and safety of capecitabine combined with a PHY906 (a pharmaceutical‐grade formulation of four traditional Chinese herbs) in the treatment of advanced hepatocellular carcinoma (HCC) in Asian patients who were positive for hepatitis B virus (HBV).MethodsThis study was an open‐label, phase II safety and efficacy clinical trial of PHY906 and capecitabine in patients with advanced HCC. Patients received 750 mg/m² capecitabine b.i.d. 14 days plus 800 mg of PHY906 b.i.d. on days 1–4 and days 8–11 every 21‐day cycle. The primary endpoint was 6‐month survival rate, and secondary endpoints were progression‐free survival, overall survival, disease control rate, and safety.ResultsThirty‐nine subjects completed the study with a 46.2% stable disease rate. The median progression‐free survival was 1.5 months, and median overall survival (mOS) was 6 months with a 51.3% 6‐month survival rate. The most common adverse events included lower hemoglobin, diarrhea, pain, abdomen (not otherwise specified), fatigue, increased aspartate aminotransferase, and bilirubin. Patients who (a) had not received previous chemotherapies or targeted therapy or (b) had lower starting alpha‐fetoprotein (AFP) levels or (c) had HBV infection showed better clinical outcome.ConclusionOur data showed that PHY906 increases the therapeutic index of capecitabine by enhancing its antitumor activity and reduces its toxicity profile in advanced HCC.     

Purification and identification of a polysaccharide from medicinal mushroom Amauroderma rude with immunomodulatory activity and inhibitory effect on tumor growth

Medicinal mushrooms in recent years have been the subject of many experiments searching for anticancer properties. We previously screened thirteen mushrooms for their potential in inhibiting tumor growth, and found that the water extract of Amauroderma rude exerted the highest activity. Previous studies have shown that the polysaccharides contained in the water extract were responsible for the anticancer properties. This study was designed to explore the potential effects of the polysaccharides on immune regulation and tumor growth. Using the crude Amauroderma rude extract, in vitro experiments showed that the capacities of spleen lymphocytes, macrophages, and natural killer cells were all increased. In vivo experiments showed that the extract increased macrophage metabolism, lymphocyte proliferation, and antibody production. In addition, the partially purified product stimulated the secretion of cytokines in vitro, and in vivo. Overall, the extract decreased tumor growth rates. Lastly, the active compound was purified and identified as polysaccharide F212. Most importantly, the purified polysaccharide had the highest activity in increasing lymphocyte proliferation. In summary, this molecule may serve as a lead compound for drug development.